Shared on 27 Oct 25
Analysts have increased their price target for Avon Technologies from £17.45 to £22.55. They cite a stronger medium-term outlook for the company.
Shared on 13 Oct 25
Fair value Increased 7.58%Anticipated Product Launches And STAR Strategy Will Strengthen Future Position In Defense And Respiratory Protection
Analysts have raised their price target for Avon Technologies from £17.45 to £22.55. They cite a strengthening medium-term outlook, supported by improved revenue growth projections, higher profit margins, and a modest increase in future earnings expectations.
Shared on 01 May 25
Fair value Increased 3.54%Anticipated Product Launches And STAR Strategy Will Strengthen Future Position In Defense And Respiratory Protection
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 23 Apr 25
Anticipated Product Launches And STAR Strategy Will Strengthen Future Position In Defense And Respiratory Protection
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Fair value Increased 3.03%Anticipated Product Launches And STAR Strategy Will Strengthen Future Position In Defense And Respiratory Protection
AnalystConsensusTarget has increased revenue growth from 7.3% to 8.1% and increased future PE multiple from 24.5x to 27.2x.
Shared on 09 Apr 25
Fair value Decreased 3.57%Anticipated Product Launches And STAR Strategy Will Strengthen Future Position In Defense And Respiratory Protection
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 6.48%Anticipated Product Launches And STAR Strategy Will Strengthen Future Position In Defense And Respiratory Protection
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Fair value Increased 3.35%Anticipated Product Launches And STAR Strategy Will Strengthen Future Position In Defense And Respiratory Protection
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Fair value Decreased 12%Anticipated Product Launches And STAR Strategy Will Strengthen Future Position In Defense And Respiratory Protection
AnalystConsensusTarget has decreased revenue growth from 8.1% to 6.9% and decreased future PE multiple from 28.8x to 24.8x.
Shared on 13 Mar 25